The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.875
Bid: 9.50
Ask: 10.25
Change: 0.175 (1.80%)
Spread: 0.75 (7.895%)
Open: 9.875
High: 9.875
Low: 9.875
Prev. Close: 9.70
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

26 Jul 2011 13:01

For filings with the FSA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are Scancell Holdings plc attached:ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify): 3. Full name of person(s) subject to the Calculus Capital Limitednotification obligation:iii 4. Full name of shareholder(s) HSBC Global Custody (UK) Limited (if different from 3.):iv 5. Date of the transaction and date on which the threshold is crossed or 26 July 2011reached: v 6. Date on which issuer notified: 26 July 2011 7. Threshold(s) that is/are crossed or 10,11,12,13%reached: vi, vii 8. Notified details: A: Voting rights attached to shares viii, ix Class/type Situation previous Resulting situation after the triggering of to the triggering transaction shares transaction Number Number Number Number of voting % of voting rightsif possible of of of shares rights x using Shares Voting the ISIN Rights Direct Direct xi Indirect Direct Indirect CODE xii Ordinary Shares ISIN: 15,277,780 15,277,780 25,277,780 25,277,780 13.02 % GB00B39J5N63 B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of Expiration Exercise/ Number of voting % of voting financial date xiii Conversion Period xiv rights that may be rights instrument acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi Resulting situation after the triggering transaction Type of Exercise price Expiration Exercise/ Number of voting % of voting financial date xvii Conversion rights instrument rights xix, xx instrument period refers to xviii Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights 25,277,780 13.02 %

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

N/A Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease N/Ato hold: 12. Date on which proxy holder will cease to hold N/Avoting rights: 13. Additional information: N/A 14. Contact name: Calculus Capital Limited 15. Contact telephone number: 0207 493 4940

Note: Annex should only be submitted to the FSA not the issuer Annex: Notification of major interests in sharesxxii A: Identity of the persons or legal entity subject to the notification obligation Full name (including legal form of legal entities) Contact address (registered office for legal entities) Phone number & email Other useful information (at least legal representative for legal persons)

B: Identity of the notifier, if applicable Full name Contact address Phone number & email Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

XLON
Date   Source Headline
9th May 20247:00 amRNSScancell presenting at 21st CIMT Annual Meeting
17th Apr 20247:00 amRNSPresenting at the Annual Immuno-Oncology Summit
16th Apr 20247:00 amRNSBlock Listing Six Monthly Return
3rd Apr 20247:00 amRNSEmployee exercise of share options
2nd Apr 20247:00 amRNSScancell to Present at 2024 AACR Annual Meeting
28th Mar 20241:21 pmRNSScancell Appoints WG as Joint Broker
26th Mar 202412:22 pmRNSFirst iSCIB1+ patient dosed
14th Mar 202411:17 amRNSAppointment of Sath Nirmalananthan to the Board
12th Mar 20247:00 amRNSScancell Attendance at Upcoming Conferences
4th Mar 20247:00 amRNSPresenting at Next-Gen Immuno-Oncology Conference
20th Feb 20247:00 amRNSChange of Auditor
5th Feb 20247:00 amRNSDirectorate Change
30th Jan 20247:00 amRNSInterim Results
26th Jan 20247:00 amRNSNotice of Interim Results and Presentation
17th Jan 20241:46 pmRNSUpdate on SCOPE trial
28th Dec 20235:36 pmRNSHolding(s) in Company
27th Dec 202311:38 amRNSHolding(s) in Company
19th Dec 20237:00 amRNSResult of the Open Offer
6th Dec 202312:41 pmRNSPDMR Notification
1st Dec 20237:00 amRNSResults of Placing
30th Nov 20235:03 pmRNSProposed Capital Raise to raise approximately £6m
29th Nov 20232:35 pmRNSResult of AGM
28th Nov 20237:00 amRNSUpdate on SCOPE trial
10th Nov 20238:32 amRNSScancell to present at 20th SMR Congress
1st Nov 20237:00 amRNSScancell to present at 38th Annual SITC meeting
31st Oct 202312:00 pmRNSNotice of AGM
31st Oct 20237:00 amRNSResults for the Year Ended 30 April 2023
20th Oct 20237:00 amRNSUpdate on Final Results
18th Oct 20237:00 amRNSScancell to speak at World Vaccine Congress Europe
17th Oct 20237:00 amRNSBlock Listing Six Monthly Return
11th Oct 20237:00 amRNSChange of Date for Final Results
3rd Oct 20237:00 amRNSNotice of Final Results and Investor Presentation
19th Sep 20237:00 amRNSPositive data from Phase 2 SCOPE trial with SCIB1
14th Sep 20237:00 amRNSScancell to present three posters at ICI
7th Sep 20237:00 amRNSScancell Appoints Head of Business Development
29th Aug 20237:00 amRNSScancell Appoints Sath Nirmalananthan as CFO
31st Jul 20237:00 amRNSModi-1 trial open for expansion in CPI combination
13th Jul 20239:14 amRNSExtension of exercise period for CEO share options
10th Jul 20237:00 amRNSPipeline strategy and business update
2nd Jun 20237:00 amRNSScancell to Present Modi-1 Data at ASCO
21st Apr 20237:00 amRNSIssue of share options to Non-Executive Directors
18th Apr 20237:00 amRNSModiFY Phase 1/2 poster presentation at AACR 2023
17th Apr 20237:00 amRNSBlock Listing Application to AIM
13th Mar 20237:00 amRNSStatement re: Silicon Valley Bank (SVB)
21st Feb 20239:05 amRNSSecond Price Monitoring Extn
21st Feb 20239:00 amRNSPrice Monitoring Extension
21st Feb 20237:00 amRNSEncouraging early efficacy data from ModiFY trial
13th Feb 20237:00 amRNSPositive response in COVIDITY trial
8th Feb 20237:00 amRNSIssue of Equity
1st Feb 20237:00 amRNSDr Jean-Michel Cosséry appointed as Chairman

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.